 Cisplatin first-line chemotherapy metastatic breast carcinoma prospective trial Italian Oncology Group Clinical Research prospective randomized study first-line treatment combination cisplatin standard cyclophosphamide methotrexate fluorouracil CMF combination patients Complete remissions assessable patients CMF assessable patients PE Complete partial remission rates CMF PE Time progression median weeks duration response weeks survival weeks different Hematologic toxicity PE gastrointestinal side effects frequent treatment study PE combination effective front-line chemotherapy response rate trend superiority CMF borderline significance Due lack survival advantage toxicity combination routine clinical use high level activity account research